tailieunhanh - Báo cáo y học: "In vivo approaches to investigate ANCA-associated vasculitis: lessons and limitations"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: In vivo approaches to investigate ANCA-associated vasculitis: lessons and limitations. | Heeringa and Little Arthritis Research Therapy 2011 13 204 http content 13 1 204 REVIEW L_ In vivo approaches to investigate ANCA-associated vasculitis lessons and limitations Peter Heeringa 1 and Mark A Little2 Abstract Anti-neutrophil cytoplasm autoantibody ANCA -associated diseases are autoimmune conditions characterized by necrotizing inflammation of small blood vessels. The immunogenesis and etiology of these conditions are unknown but our knowledge of the immunopathogenesis has increased considerably in recent years. In this review we discuss the animal models currently used to investigate the mechanisms of vascular injury and to test novel therapies. We outline their advantages and limitations and propose potential directions for future research. Introduction Anti-neutrophil cytoplasm autoantibody ANCA -asso-ciated systemic small vessel vasculitis SVV comprising Wegener granulomatosis and microscopic polyangiitis is a group of related autoimmune disorders characterized by inflammatory necrosis of small blood vessels 1 . This results in dysfunction of supplied organs and the principal clinical consequences are renal failure and lung hemorrhage. If the condition is untreated the mortality at 1 year is almost 90 2 . Despite modern treatment protocols there are still mortality rates of 15 and 36 at 1 and 5 years respectively 3 significantly higher than other autoimmune diseases and certain malignancies. The immunosuppressive therapies used carry a heavy burden of adverse events one recent study found that death in the first year is three times more likely to be due to an adverse event than to the vasculitis itself 4 . In those patients not recovering renal function renal replacement therapy carries an additional average annual cost of 31 000 to 40 000 42 240 to 54 500 per patient. Correspondence department of Pathology and Medical Biology University Medical Centre Groningen University of Groningen Hanzeplein 1